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 Background: Several factors determine the efficacy of warfarin anticoagulation in patients with non-valvular atrial fibrilla-
tion (NVAF). This study aimed to use data from the Chinese Atrial Fibrillation Registry study to assess the con-
trol of anticoagulation therapy in Chinese patients with NVAF treated with warfarin.
 Material/Methods: From the Chinese Atrial Fibrillation Registry study the anticoagulant use and dosing, the time in therapeu-
tic range (TTR) of the international normalized ratio (INR), and standard deviation of the observed INR values 
(SDINR), and their influencing factors were evaluated.
 Results: The median INR and SDINR were 2.04 (IQR 1.71–2.41) and 0.50 (IQR, 0.35–0.69), respectively. The median TTR 
was 51.7% (IQR, 30.6–70.1%) and only 25.1% had a TTR ³70%. Age was ³70 years (OR, 0.72; 95% CI, 0.55–0.94; 
P=0.015), bleeding history (OR 0.48; 95% CI, 0.23–0.89; P=0.029), the use of a single drug (OR, 0.62; 95% CI, 
0.42–0.92; P=0.016), more than drug (OR, 0.60; 95% CI, 0.41–0.88; P=0.009), and lack of assessment of bleed-
ing risk (OR, 0.72; 95% CI, 0.54–0.97; P=0.033) were associated with TTR <70% (INR 2.0–3.0). Coronary heart 
disease (CHD) and peripheral artery disease (PAD) (OR, 0.69; 95% CI, 0.52–0.90; P=0.007) and diabetes melli-
tus (OR, 0.79; 95% CI, 0.62–0.99; P=0.044) were associated with increased variability in INR (SDINR ³0.5).
 Conclusions: In Chinese patients with NVAF, warfarin anticoagulation was associated with lower TTR and less stable antico-
agulation than in current guidelines, and risk factors for reduced safety and efficacy were identified.
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Background
The vitamin K antagonists that include warfarin are highly ef-
fective for the prevention of stroke in patients with atrial fi-
brillation (AF) [1]. An appropriate degree of anticoagulant and 
maintenance of stable anticoagulation are important in balanc-
ing the benefits of warfarin in the prevention of stroke and in 
avoiding the risk of bleeding [2]. It is has been assumed that 
Asian populations are at a higher risk of bleeding when treat-
ed with warfarin [3]. The Chinese Atrial Fibrillation Registry 
study is a hospital-based, multicenter, prospective registry 
study, that includes real-world data of approximately 20,000 
patients with AF [4]. An international normalized ratio (INR) 
target range of 2.0–3.0 is recommended by the Chinese Atrial 
Fibrillation Registry management guidelines [4], and an INR 
range of 1.6–2.6 has been recommended for patients with AF 
who are ³70 years old by the Japanese Circulation Society [5,6].
In China, there are limited data on the degree of anticoagu-
lation required in real-world clinical practice and on the fac-
tors that influence the effectiveness of anticoagulation. In 
this study, we identified patients with nonvalvular atrial fi-
brillation (NVAF) taking long-term warfarin therapy from the 
Chinese Atrial Fibrillation Registry study. Quality of anticoag-
ulation control as reflected by time in therapeutic range (TTR) 
of the international normalized ratio (INR) and anticoagula-
tion stability, or the standard deviation of INR (SDINR), were 
evaluated [7,8]. Factors associated with TTR ³70% and anti-
coagulation stability were also analyzed. This study aimed to 
use data from the Chinese Atrial Fibrillation Registry study to 
assess the control of anticoagulation therapy in Chinese pa-
tients with NVAF treated with warfarin.
Material and Methods
Study population
The Chinese Atrial Fibrillation Registry study is a prospective, 
multicenter, hospital-based, ongoing registry study of patients 
with atrial fibrillation (AF) in Beijing, China [4]. Thirty-one ter-
tiary and non-tertiary hospitals in Beijing that treated patients 
with AF were included in the study [9]. Each patient signed an 
informed consent before enrolment. We extracted the data of 
patients with AF treated with warfarin from the Chinese Atrial 
Fibrillation Registry study from August 1, 2011, to June 30, 
2016 [4]. Exclusion criteria included age <18 years, rheumatic 
valvular disease, others diseases with life expectancy <6 months, 
with anticoagulation therapy other than warfarin, number of 
INR values <5, the maximal interval between two successive INR 
values >90 days and follow-up period of more than six months. 
The INR values of the first six weeks of the patients who had 
recently commenced treatment with warfarin were excluded.
Data collection
Relevant information about warfarin treatment, including the 
date of starting and stopping warfarin, and all INR values dur-
ing the time period were collected. To minimize missing data, 
INR values from the hospital information system (HIS) of par-
ticipating hospitals were extracted and integrated with those 
from Chinese Atrial Fibrillation Registry database.
Baseline information included demographic characteristics in-
cluding age, gender, history of smoking, alcohol consumption, 
comorbidities that included hypertension, diabetes mellitus, 
heart failure, stroke, transient ischemic attack (TIA), throm-
boembolism, peripheral artery disease (PAD), bleeding histo-
ry, and coronary heart disease (CHD), was collected. Patients 
were followed up in the third month, sixth month, and every 
six months after that. Data were collected on the use of anti-
platelet agents and other concomitant drugs, including anti-
arrhythmic drugs, drugs to control ventricular rate, angioten-
sin-converting enzyme (ACE) inhibitors, angiotensin receptor 
blockers (ARBs), and statins.
Ethics
This study was approved by the Beijing Anzhen Hospital Ethics 
Committee (No. D11110700300000) on June 10, 2011.
Quality	of	anticoagulation	control	and	stability	of	warfarin
The time in the different therapeutic range of INR (TTR) was cal-
culated using the Rosendaal method [10]. TTR ³70% was con-
sidered as high-quality INR control according to the European 
Society of Cardiology (ESC) guidelines [7]. The distribution of 
TTR and INR reflected the quality of anticoagulation control in 
the warfarin-treated patients. Anticoagulation stability was as-
sessed using the standard deviation (SD) of observed INR val-
ues (SDINR) of each participating patient [8]. In this study, SDINR 
<median (0.5) was considered as high anticoagulation stability.
Definitions
A score for bleeding risk was derived from the Atrial Fibrillation 
Effect on Quality-of-life (AFEQT) score [11]. The risk of bleed-
ing was scored on a 1–7 Likert scale (ranging from 1, not at 
all, to 7, extremely). We defined 1–2, 3, and 4–7 as low, mod-
erate, and high levels of bleeding risk, respectively. The risk 
of stroke for each patient was evaluated using the CHA2DS2-
VASc score, which included congestive heart failure, hyper-
tension, diabetes mellitus, vascular disease including coro-
nary heart disease (CHD) or peripheral arterial disease (PAD), 
female gender, and age between 64–75 years contributed 1 
point and 2 points each for stroke, TIA, thromboembolism his-
tory and age ³75 years [12–14].
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HAS-BLED was used as a scoring system for bleeding risk with 
1 point (range, 0–9) assigned for the presence of each of the 
following: old age, hypertension, abnormal liver or renal func-
tion, a previous stroke, a history of bleeding, unstable INRs, 
concomitant drugs or alcohol excess [15]. A HAS-BLED score 
of ³3 indicated an increased risk of bleeding [15].
SAMe-TT2R2 score was calculated using the factors of fe-
male gender, age (<60 years), medical history, with at least 
two of the following: hypertension, diabetes mellitus, CHD, 
PAD, congestive heart failure, stroke history, pulmonary dis-
ease, hepatic or renal disease. Treatment, with interacting 
drugs such as amiodarone, contributed 1 point respective-
ly and 2 points each for current tobacco use and race (non-
Caucasian) [16].
Statistical analysis
Continuous variables were reported as the mean ± standard 
deviation (SD), or the median (IQR 25–75%), and categorical 
variables as n (%). A multivariate logistic regression model was 
constructed to identify the associated factors independently 
associated with the degree of anticoagulation and stability. 
In the model, we adjusted age, gender, history of stroke, TIA, 
thromboembolism, history of bleeding, history of myocardial 
infarction, known CHD or PAD, diabetes mellitus, hypertension, 
congestive heart failure, anemia, combined platelet agents, 
current smoking, current drinking, bleeding risk score, combi-
nation medication, CHA2DS2-VASc score and HAS-BLED score. 
Data were analyzed using SAS version 9.2 software. P<0.05 
was considered to be statistically significant.
Results
A total of 1,895 eligible patients with a mean age of 66.78±9.60 
years (56.5% were men) who were treated with warfarin were 
included in this study. Only 24.8% of patients with non-val-
vular atrial fibrillation (NVAF) in the Chinese Atrial Fibrillation 
Registry met the inclusion criteria for this study. The patient 
inclusion process for this study is shown in Figure 1. Baseline 
characteristics of the included patients are shown in Table 1.
Distribution of the international normalized ratio (INR) 
values
We collected 29,335 international normalized ratio (INR) values 
during a median follow-up time of 1,094 days (IQR, 729–1,609 
days). The median interval of INR testing was 29 days (IQR, 
23–38 days). The number of INR tests for each patient ranged 
from 5–114, with a median of 9 (IQR, 6–18). INR values ranged 
from 0.69–19.85, with a median of 2.04 (range, 1.7–2.4). The 
density distribution of INRs is shown in Figure 2.
When the INR target range was set as 2.0–3.0, only 475 pa-
tients (25.1%) had a TTR ³70%, and 724 patients (38.2%) had 
a TTR ³60%. The median TTR was 51.7% (IQR, 30.6–70.1%)]. 
The mean time distribution of the INR under the low bound-
ary of therapeutic range (INR <2.0) was significantly high-
er than that above the upper boundary of the therapeutic 
range (INR >3.0) [42.0% (IQR, 22.5–65.0%) versus 0.33% (IQR, 
0.0–5.8%), p<0.01], the median time distributions of INR <2.0 
were 44.90±28.18% versus 5.07±9.82% for INR >3.0 (p<0.01).
With regard to different INR ranges of <1.6, 1.6–2.0, 2.0–2.6, 
2.6–3, and ³3, the time distributions of INR were not significant-
ly different in the different patient subgroups (<70 years or ³70 
years, female or male, with or without history of stroke, TIA, or 
thromboembolism, with or without history of bleeding, CHA2DS2-
VASc score <2 or ³2, HAS-BLED score 0–2 or >2 (all, P>0.05).
If we set the INR target range as 1.6–2.6, 1123 (59.3%) pa-
tients had a TTR ³70%. The median TTR was 75.2% (IQR, 57.0–
88.3%), significantly higher than the proportion when INR tar-
get range was set as 2.0–3.0, with a median of 51.7% (IQR, 
30.6–70.1%) (p<0.0001) (Figure 3).
Variability of anticoagulation intensity
The median SDINR was 0.50 (IQR, 0.35–0.69). The SDINR was not 
significantly different in subgroups of age <70 or ³70 years, 
male and female, with or without a history of stroke, TIA, or 
thromboembolism and bleeding, higher or lower bleeding risk 
score, CHA2DS2-VASc score and HAS-BLED score (all, P>0.05) 
(Supplementary Table 1).
8939 AF patients, 61698 INR values
7645 NVAF patients, 55118 INR values
2596 NVAF patients, 38577 INR values
1910 NVAF patients, 29546 INR values
1895 NVAF patients, 29335 INR values
1294 (14.5%) patients with valvular AF
and with novel oral anticoagulants were
excluded
686 (7.7%) patients with maximize
interval between two successive INR
values>90 days were excluded
5049 (14.5%) patients with <5 INR were
excluded
15 (0.17%) patients followed up <6
months were excluded
Figure 1.  Flowchart of the patient recruitment in this study.
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Factors associated with anticoagulation intensity and 
stability
Multivariate logistic regression showed that for INR target range 
of 2.0–3.0, age ³70 years, history of bleeding, low bleeding risk 
score, and concomitant drugs were independently associated 
with a TTR <70%. When the INR target range was 1.6–2.6, these 
factors were no longer significantly related to the TTR (Table 2). 
Multivariate logistic regression analysis showed that a history 
of myocardial infarction, CHD, PAD, and diabetes mellitus re-
sulted in worse INR stability (SDINR ³0.5) (Table 3).
Discussion
This study used data from the Chinese Atrial Fibrillation Registry 
study to assess the control of anticoagulation therapy in pa-
tients with non-valvular atrial fibrillation (NVAF) treated with 
warfarin. The distribution of the international normalized ra-
tio (INR) values and the mean time in therapeutic range (TTR) 
showed that the quality of anticoagulation control was gen-
erally suboptimal. Also, for the INR target range of 2.0–3.0, 
age ³70 years, history of bleeding, low bleeding risk score, 
and concomitant drugs were independently associated with 
a TTR <70%. The variability in INR was significantly associat-
ed with a history of coronary heart disease (CHD), peripheral 
arterial disease (PAD), and diabetes mellitus.
From this study, warfarin anticoagulation intensity was shifted 
towards lower INR ranges, with a median INR of 2.04, and the 
median time distribution proportion of INR <2 was more than 
40%, compared with an INR >3 (less than 1%), the mean time 
distribution proportion were 44.90% and 5.07%. In the ROCKET 
AF trial, the mean time distribution proportion under the INR 
range <2 and >3 accounted for 29.1% and 15.7%, respective-
ly [2]. Time distribution proportion of INR had the same ten-
dency to each subgroup whether categorized by age, gender, 
history of stroke or transient ischemic attack (TIA), pulmonary 
embolism, bleeding history, CHA2DS2-VASc score, or HAS-BLED 
score, suggesting that the status of anticoagulation intensi-
ty that was shifted to left did not vary based on thromboem-
bolic or bleeding risk. However, the CHA2DS2-VASc score and 
0 1 2 3
1.71 2.04 2.41
INR value
4 5 6
De
ns
ity
0.8
0.6
0.4
0.2
0.0
Figure 2.  Distribution of the international normalized ratio (INR) 
in 1,895 patients with non-valvular atrial fibrillation 
(NVAF) treated with warfarin. Density: frequency/
distance=percent/0.1. IQR – interquartile range.
Characteristics Total (N=1895)
Age, (y)  66.78±9.60
Male  1071 (56.5)
Current drinking*  336/1886 (17.8)
Current smoking*  235/1886 (12.5)
Atrial fibrillation type
 Newly diagnosed  91 (4.8)
 Paroxysmal  853 (45.0)
 Persistent  951 (50.2)
Comorbidities
 Congestive heart failure  287 (15.1)
 Hypertension  1331 (70.2)
 Diabetes mellitus  535 (28.2)
 Stroke/TIA/thromboembolism  456 (24.1)
 Anemia  60 (3.2)
 Prior MI/known CHD/PAD  337 (17.8)
 Chronic kidney disease  7 (0.4)
 Bleeding history  109 (5.8)
Medication
 Antiplatelet agents  334 (17.6)
 Antiarrhythmic drugs  476 (25.1)
 Rate control drugs  1210 (63.9)
 ACEI/ARB  770 (40.6)
 Statin  785 (41.4)
Score
 Bleeding risk  3.11±1.00
 CHA2DS2-VASc score  3.09±1.71
 HAS-BLED score  2.60±1.15
 SAMe-TT2R2 score  3.64±1.07
Table 1. Patient characteristics.
Data were indicated as mean ± standard deviation (SD) of 
the number (%); * N of total, 1886; N of age <70 years, 1068; 
N of age ³70 years, 818. Angiotensin converting enzyme (ACE) 
inhibitors, angiotensin receptor blockers (ARBs). TIA – transient 
ischemic attack; MI – myocardial infarction; CHD – coronary 
heart disease; PAD – peripheral artery disease.
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11.9
12.1
29.9
30.6
43.7
43.1
9.6
9.6
4.9
4.6
11.9
12.7
>2 (n=554)
≤2 (n=1341)
≥2 (n=1536)
<2 (n=359)
No (n=1786)
Yes (n=109)
No (n=1439)
Yes (n=456)
Female (n=824)
Male (n=1071)
≥702 (n=822)
<70 (n=1073)
HAS-BLED score
CHA2DS2-VASc score
Bleeding history
Stroke history
Sex
Age
0 10 20 30 40 50 60 70 80 90 100 %
30.6
29.1
43.2
44.3
9.6
9.7
4.7
4.2
12
12.3
30.1
33.9
43.7
38.5
9.6
10
4.7
5.3
12.1
11.9
30.8
29.2
43.2
43.5
9.3
10.4
4.6
5
12.5
11.7
31.4
29.5
42.1
44.2
9.4
9.8
4.6
4.8
11.7
12.4
31.6
29
43.2
43.5
9
10.3
4.5
4.8
<1.6 1.6–2.0 2.0–2.6 2.6–3.0 ≥3.0
Figure 3.  The comparison of the proportion of 
time of the international normalized 
ratio (INR) within subgroups, the HAS-
BLED score, the CHA2DS2-VASc score, 
history of bleeding, stroke, transient 
ischemic attack (TIA), history of 
thromboembolism, gender, and age 
(p<0.05).
Characteristics
INR Target ranges of 2.0-3.0 INR Target range of 1.6-2.6
n/N (%) O R(95% CI) P value n/N(%) OR(95% CI) P value
Age ³70 y 177/822  0.72 (0.55–0.94) 0.015 473/822  0.93 (0.73–1.17) 0.531
Male 274/1071  0.96 (0.74–1.26) 0.786 654/1071  1.16 (0.92–1.46) 0.224
Stroke/TIA/thromboembolism 115/456  1.05 (0.74–1.48) 0.798 274/456  1.14 (0.84–1.56) 0.393
Bleeding history 16/109  0.48 (0.23–0.89) 0.029 64/109  0.95 (0.59–1.53) 0.824
Prior MI/known CHD/PAD 84/337  1.16 (0.84–1.57) 0.361 207/337  1.11 (0.84–1.47) 0.458
Diabetes mellitus 137/535  1.05 (0.8–1.36) 0.737 337/535  1.17 (0.92–1.49) 0.195
Hypertension 336/1331  1.27 (0.93–1.75) 0.13 775/1331  0.95 (0.72–1.25) 0.704
Congestive heart failure 60/287  0.83 (0.58–1.17) 0.285 174/287  1.11 (0.83–1.51) 0.483
Anemia 14/60  0.97 (0.48–1.84) 0.931 30/60  0.68 (0.39–1.2) 0.184
Combined platelet agents 82/334  1.07 (0.73–1.55) 0.739 195/334  1.07 (0.77–1.5) 0.675
Current smoking 67/336  1.08 (0.74–1.56) 0.679 137/235  0.81 (0.58–1.15) 0.236
Current drinking 93/235  1.1 (0.76–1.59) 0.603 209/336  1.27 (0.91–1.77) 0.165
Bleeding risk score <3 81/373  0.72 (0.54–0.97) 0.033 220/373  0.97 (0.75–1.26) 0.834
Bleeding risk score >3 95/395  0.82 (0.62–1.09) 0.178 226/395  0.91 (0.71–1.17) 0.456
*Concomitant drug (n=1) 128/527  0.62 (0.42–0.92) 0.016 327/527  1.24 (0.86–1.79) 0.243
*Concomitant drugs (n³2) 284/1169  0.6 (0.41–0.88) 0.009 680/1169  0.93 (0.65–1.32) 0.694
CHA2DS2 –VASc score ³2 376/1536  1.05 (0.71–1.55) 0.806 907/1536  1.09 (0.77–1.53) 0.639
**HAS-BLED score >2 132/554  0.95 (0.64–1.43) 0.821 319/554  0.85 (0.6–1.22) 0.379
Table 2.  Multivariate logistic regression analysis of factors associated with the time in therapeutic range (TTR) ³70% with different 
international normalized ratio (INR) target ranges.
* Concomitant drugs include antiarrhythmic drugs, ventricular rate control drugs, angiotensin converting enzyme (ACE) inhibitors, 
angiotensin receptor blockers (ARBs), and statins. ** Excluding labile INR. Total number=1895. Total number of TTR ³70%=475 
(INR range, 2.0–3.0). Total number of TTR ³70%=1123 (INR range, 1.6–2.6). TIA – transient ischemic attack; MI – myocardial infarction; 
CHD – coronary heart disease; PAD – peripheral artery disease.
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HAS-BLED scores were not associated with the degree of an-
ticoagulation. Physicians do not often treat patients based on 
their risk [17–19]. Notably, the median INR in our study was 
2.04, which was close to the recommended INR target range of 
1.6–2.6 for patient age ³70 years by the Japanese Circulation 
Society [5,6], although guidelines from China recommend the 
INR target range should be 2.0–3.0. The optimal INR range for 
warfarin use is debated in Asian populations because of the 
limited evidence from controlled studies [20]. It has been be-
lieved that Asian patients have an increased risk of hemor-
rhage because of race, genetics, and lifestyle differences [21]. 
Therefore, both physicians and patients appear more concerned 
about bleeding risk related to warfarin anticoagulation and aim 
for lower INR ranges. However, the TTR is a stronger determi-
nant of bleeding risk than the INR values [22,23].
In this study, multivariate logistic regression analysis showed 
that age ³70 years and bleeding history were independent risk 
factors associated with TTR. Reduced concern regarding the 
risk of bleeding may increase the compliance with and the ef-
fectiveness of anticoagulation. Therefore, patients undergoing 
warfarin anticoagulation therapy require education and sup-
port to improve their compliance with optimal anticoagulation 
therapy. Concomitant drug use is also independently associat-
ed with TTR, and is probably related to the interaction of var-
ious drugs in the body.
As this study showed, the standard deviation (SD) of observed 
INR values (SDINR) is an important index of the INR variability, 
reflecting INR fluctuations, either outside or within the ther-
apeutic window. The variability of INR is an important factor 
associated with the anticoagulation effects of warfarin, which 
is related directly to prognosis in patients on warfarin thera-
py [8,24,25]. In this study, INR fluctuation was associated with 
the patient history of CHD, PAD, and diabetes mellitus, which 
suggested these comorbidities significantly impacted the sta-
bility of anticoagulation. Attention to these comorbidities as 
part of a holistic and integrated approach to the management 
of AF would improve clinical outcomes [26–28].
The results of the present study showed that the quality of an-
ticoagulation control using warfarin was suboptimal and this 
was associated with several factors that included age, comor-
bidities, concomitant drugs, and the attitudes of the physician 
and patient. It has been assumed that the stability of warfarin 
anticoagulation in Asian patients is worse than in European 
Characteristics n/N(%) OR (95% CI) P value
Age ³70 y 424/822  1.08 (0.85–1.36) 0.541
Male 533/1071  1.12 (0.89–1.41) 0.342
Stroke/TIA/TE 229/456  1.20 (0.88–1.62) 0.244
Bleeding history 54/109  0.98 (0.61–1.58) 0.946
Prior MI/known CHD/PAD 141/337  0.69 (0.52–0.90) 0.007
Diabetes mellitus 242/535  0.79 (0.62–0.99) 0.044
Hypertension 661/1331  1.23 (0.94–1.62) 0.135
Congestive heart failure 124/287  0.88 (0.66–1.18) 0.404
Anemia 26/60  0.97 (0.55–1.7) 0.908
Combined antiplatelet agents 152/334  1.05 (0.76–1.46) 0.765
Current smoking 121/336  1.25 (0.89–1.75) 0.196
Current drinking 158/235  0.87 (0.63–1.2) 0.39
Bleeding risk score <3 177/373  0.86 (0.66–1.1) 0.223
Bleeding risk score >3 203/395  1.03 (0.8–1.32) 0.817
*Concomitant drug (n=1) 269/527  0.79 (0.55–1.13) 0.204
*Concomitant drugs (n³2) 564/1169  0.84 (0.59–1.2) 0.341
CHA2DS2 –VASc score ³2 755/1536  1.05 (0.75–1.48) 0.772
**HAS-BLED score >2 261/554  0.76 (0.53–1.07) 0.119
Table 3. Multivariate analysis of associate factors of SDINR <0.5.
* Concomitant drugs include antiarrhythmic drugs, ventricular rate control drugs, angiotensin converting enzyme (ACE) inhibitors, 
angiotensin receptor blockers (ARBs), and statins. ** Excluding labile INR. Total number of SDINR <0.5=940. TIA – transient ischemic 
attack; MI – myocardial infarction; CHD – coronary heart disease; PAD – peripheral artery disease.
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and American patients [21]. The use of a clinical score helped 
to identify patients with AF who were less likely to do well on 
warfarin and included the SAMe-TT2R2 score, which in non-
Caucasians was assigned 2 points [16]. Those patients with a 
SAMe-TT2R2 score ³2 may require additional methods to im-
prove the effects of anticoagulation, such as more frequent 
INR checks, education, and counseling [29].
Whether vitamin K antagonists or new oral anticoagulants 
(NOACs) are used, medication adherence is central to the pre-
vention of thromboembolism. Although the use of NOACs is 
increasing, patients with valvular heart diseases and a high 
proportion of patients with non-valvular AF will still be on war-
farin in China. Therefore, a multidisciplinary approach, includ-
ing education of healthcare professionals, implementation of 
local guidelines, multidisciplinary medical care programs, and 
healthcare system support are needed to improve the quality 
of anticoagulant control [30,31].
This study had several limitations. First, Chinese patients with 
AF on long-term warfarin were identified from the Chinese Atrial 
Fibrillation Registry study [4]. It may be difficult to apply the find-
ings from this study to other regions of China, as the Chinese 
Atrial Fibrillation Registry study mainly registered patients from 
Beijing. We identified patients with NVAF undergoing long-term 
warfarin therapy, and therefore, the patients included in this 
study had good compliance with their medication. Study indi-
ces that included warfarin use and discontinuation rates also are 
important factors reflecting the quality of warfarin anticoagula-
tion, but these factors were not recorded in this study, but have 
been previously reported in other studies [32,33].
Conclusions
This study aimed to use data from the Chinese Atrial Fibrillation 
Registry study to assess the control of anticoagulation therapy 
in Chinese patients with non-valvular atrial fibrillation (NVAF) 
treated with warfarin. The study findings showed that the 
quality of warfarin anticoagulation in Chinese patients with 
NVAF was generally lower than that recommended in current 
clinical guidelines. Increased age, a history of bleeding, con-
comitant drug therapies, and insufficient attention to bleed-
ing risk were associated with reduced time in the therapeutic 
range (TTR) of the international normalized ratio (INR). A pre-
vious history of coronary heart disease (CHD), peripheral ar-
terial disease (PAD), and diabetes mellitus were factors asso-
ciated with reduced stability of anticoagulation.
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Characteristics
SDINR
p-Value
Median (25–75%)
Age 
 <70y 0.52 (0.37-0.68)
P=0.082
 ³70y 0.49 (0.36-0.65)
Gender
 Male 0.50 (0.36-0.66)
P= 0.607
 Female 0.50 (0.37-0.68)
Stroke/TIA/thromboembolism
 Yes 0.50 (0.36-0.66)
P= 0.740
 No 0.50 (0.37-0.67)
Bleeding history
 Yes 0.50 (0.40-0.67)
P=0.926
 No 0.50 (0.36-0.67)
Supplement Table 1. Variability of anticoagulation intensity.
TIA – transient ischemic attack. The comparison of the SDINR 
within subgroups defined by HAS-BLED score, CHA2DS2-
VASc score, bleeding risk score, bleeding or stroke/TIA/
thromboembolism history, gender, and age (p>0.05)
Characteristics
SDINR
p-Value
Median (25–75%)
Bleeding risk score
 <3 0.51 (0.40-0.70)
P=0.099 =3 0.50 (0.35-0.66)
 >3 0.49 (0.37-0.65)
CHA2DS2 – VASc score
 <2 0.49 (0.36-0.66)
P=0.497
 ³2 0.51 (0.36-0.67)
HAS-BLED score
 £2 0.50 (0.36-0.66)
P=0.087
 >2 0.52 (0.38-0.70)
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